Home    Back

 277. Lymphangiomatosis
 [ 6 clinical trials,    2 drugs(DrugBank: 2 drugs),    1 target gene / 43 target pathways

Searched query = "Lymphangiomatosis", "Generalized lymphatic anomaly", "Gorham disease", "Gorham Stout disease", "Diffuse lymphangiomatosis", "Mass osteolysis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs03118029016/11/20177 October 2019A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomaliesA multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies - Sirolimus for intractable vascular anomaliesIntractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lympha
Vascular disorders
Body surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.
BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.
Michio OzekiRecruitingNot applicableNot applicableBoth50Phase 3none
2JPRN-UMIN0000305222017/11/142 April 2019A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomaliesIntractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lymphatic anomaly, Kaposiform lymphangiomatosis), Gorham-Stout disease, Kaposiform hemangioendothelioma and Tuffted angioma with Kasabach-Merritt phenomenon, Nenous malformation, Arteriovenous malformation, Klippel-Trenaunay-Weber syndrome,Bluerubber bleb nevus syndrome, Complex-combined vascular malformationsBody surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.
BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.
Gifu UniversityRecruitingNot applicableNot applicableMale and Female50Not selectedJapan
3JPRN-UMIN0000298432017/11/062 April 2019Sirolimus for the treatment of refractory lymphangiomatosis/ Gorham Stout diseaseRefractory lymphangiomatosis, Gorham-Stout diseaseOral sirolimusKyushu University HospitalRecruiting8years-old30years-oldMale and Female2Not selectedJapan
4JPRN-UMIN0000165802015/02/012 April 2019Sirolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomaliesSirolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomalies - Sirolimus for vascular anomaliesLymphangiomatosis, Gorham-Stout disease and vascular anomaliesOral sirolimusGifu universityNot RecruitingNot applicable30years-oldMale and Female30Phase 1,2Japan
5JPRN-UMIN0000148882014/06/012 April 2019Everolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomaliesLymphangiomatosis, Gorham-Stout disease and vascular anomaliesOral everolimusGifu universityNot RecruitingNot applicable30years-oldMale and Female30Phase 1Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00975819October 200919 February 2015Safety and Efficacy Study of Sirolimus in Complicated Vascular AnomaliesA Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular AnomaliesKaposiform Hemangioendotheliomas;Tufted Angioma;Capillary Venous Lymphatic Malformation;Venous Lymphatic Malformation;Microcystic Lymphatic Malformation;Mucocutaneous Lymphangiomatosis and Thrombocytopenia;Capillary Lymphatic Arterial Venous Malformations;PTEN Overgrowth Syndrome With Vascular Anomaly;Lymphangiectasia SyndromesDrug: sirolimusChildren's Hospital Medical Center, CincinnatiNot recruitingN/A31 YearsBoth60Phase 2United States

Back to top